Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, ...

View Structure Therapeutics, Inc. Sponsored ADR GPCR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Structure Therapeutics recently reported in Nature Medicine and at the American Diabetes Association’s 86th Scientific Sessions that its oral GLP-1 receptor agonist aleniglipron achieved statistically ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ...

Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:00 AM EDTCompany ParticipantsRaymond ...

Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Through an international collaboration, scientists at St. Jude Children’s Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...